RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Depreciation & amortization

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndDepreciation & amortization (Million USD)YoY (%)
Dec 31, 2024207+14.29%
Dec 31, 2023181+22.25%
Dec 31, 2022148+18.07%
Dec 31, 2021126+14.69%
Dec 31, 2020110+2.41%
Dec 31, 2019107+47.67%
Dec 31, 201872+17.95%
Dec 31, 201761-0.00%
Dec 31, 201661-1.52%
Dec 31, 201562-1.44%
Dec 31, 201463+30.79%
Dec 31, 201348+26.64%
Dec 31, 201238+8.99%
Dec 31, 201135+15.04%
Dec 31, 201030

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)